Published: Guidance, quality standards and advice
Showing 11 to 14 of 14
| Title | Reference number | Published | Last updated |
|---|---|---|---|
| Targeted-release budesonide for treating primary IgA nephropathy | TA937 | ||
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over | TA1101 | ||
| Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | TA1099 | ||
| Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) | TA1100 |